Objective To observe the effect of defibrase on serum hypersensitive C-reactive protein (hs-CRP), D-dimer (D-D), National Institute of Health stroke scale (NIHSS) score and activities of daily living scale (Barthel in-dex) in patients with acute cerebral infarction. Methods Ninety-eight patients with acute cerebral infarction in our hos-pital from June 2014 to June 2015 were randomly divided into the observation group (n=49) and the control group (n=49) according to the random number table. The control group was given conventional treatment, and the observation group was treated with defibrase on the basis of the control group. The two groups were both treated for 2 weeks. The se-rum hs-CRP, D-D, NIHSS score, Barthel index score and clinical curative effect of patients before treatment, and after treatment for 3 days, 1 week, 2 weeks were compared between the two groups. Results The serum hs-CRP, D-D of pa-tients after treatment for 3 days, 1 week, 2 weeks in the two groups were significantly lower than those before treatment, and the differences were statistically significant (P<0.05). The serum hs-CRP of observation group after treatment for 3 days (8.21 ± 2.76) mg/L, 1 week (6.54 ± 1.84) mg/L, 2 weeks (3.25 ± 0.95) mg/L were significantly lower than those of the control group for 3 days (9.37±2.85) mg/L, 1 week (7.78±2.10) mg/L, 2 weeks (4.36±1.12) mg/L. The serum D-D of obser-vation group after treatment for 3 days (351.31±85.52)μg/L, 1 week (291.54±55.43)μg/L, 2 weeks (243.56±50.78)μg/L were significantly lower than those of the control group for 3 days (388.47±91.34)μg/L, 1 week (320.82±70.37)μg/L, 2 weeks (282.63 ± 68.46)μg/L. The NIHSS score of observation group after treatment for 1 week (8.41 ± 2.13), 2 weeks (4.94±1.22) were significantly lower than those of the control group (9.46±2.30), (5.37±1.73). The Barthel index of observation group after treatment for 1 week [(68.74±13.56)], 2 weeks (78.54±15.27) were significantly higher than those of the control group of (60.43 ± 13.42), (72.17 ± 14.64). The effective rate in observation group after treatment 89.8%(44/49) was significantly higher than that in control group 73.5%(36/49), and the difference was statistically sig-nificant (P=0.05). There were no serious adverse reactions in the two groups during the treatment. Conclusion Defi-brase can reduce the levels of serum hs-CRP and D-D in patients with acute cerebral infarction, improve the body's in-flammatory and hypercoagulative state, and promote the recovery of neurological deficits and the improvement of the ac-tivities of daily living.%目的：观察降纤酶对急性脑梗死患者血清超敏C反应蛋白(hs-CRP)、D-二聚体(D-D)及美国国立卫生院神经功能缺损评分(NIHSS)和日常生活活动能力量表(Barthel指数)的影响。方法将2014年6月至2015年6月我院收治的98例急性脑梗死患者按随机数表法分为观察组(n=49)和对照组(n=49)，对照组给予常规治疗，观察组在对照组的基础上加用降纤酶治疗，两组均治疗2周。比较两组患者治疗前及治疗后3天、1周、2周的血清hs-CRP、D-D、NIHSS评分、Barthel指数评分及临床疗效。结果两组患者治疗后3天、1周、2周的血清hs-CRP、D-D均较治疗前降低，差异均有统计学意义(P<0.05)；观察组治疗后3 d [(8.21±2.76) mg/L]、1周[(6.54±1.84) mg/L]、2周[(3.25±0.95) mg/L]的血清hs-CRP低于对照组3 d [(9.37±2.85) mg/L]、1周[(7.78±2.10) mg/L]、2周[(4.36±1.12) mg/L]；观察组治疗后3 d [(351.31±85.52)μg/L]、1周[(291.54±55.43)μg/L]、2周[(243.56±50.78)μg/L]的血清D-D低于对照组3 d [(388.47±91.34)μg/L]、1周[(320.82±70.37)μg/L]、2周[(282.63±68.46)μg/L]；观察组治疗后1周[(8.41±2.13)分]、2周[(4.94±1.22)分]的NIHSS评分低于对照组[(9.46±2.30)分、(5.37±1.73)分]；观察组治疗后1周[(68.74±13.56)分]、2周[(78.54±15.27)分]的Barthel指数高于对照组[(60.43±13.42)分、(72.17±14.64)分]。以上各项指标比较，差异均有统计学意义(P<0.05)。观察组治疗后的治疗有效率[89.8%(44/49)]高于对照组[73.5%(36/49)]，差异有统计学意义(χ2=4.349，P=0.037)。两组治疗期间均未出现严重的不良反应。结论降纤酶治疗能够降低急性脑梗死患者的血清hs-CRP及D-D水平，改善机体的炎性及高凝状态、促进患者神经缺损功能恢复及日常生活活动能力的改善。
展开▼
